Suppr超能文献

血小板活化因子(PAF)上调大鼠血浆和组织中PAF - 乙酰水解酶的活性:环己酰亚胺的作用

Platelet-activating factor (PAF) up-regulates plasma and tissue PAF-acetylhydrolase activity in the rat: effect of cycloheximide.

作者信息

Wang H, Tan X D, Qu X W, Chang H, Remick D G, Gonzalez-Crussi F, Hsueh W

机构信息

Department of Pathology, Children's Memorial Hospital, Northwestern University Medical School, Chicago, Illinois 60611, USA.

出版信息

Pediatr Res. 1997 Nov;42(5):597-603. doi: 10.1203/00006450-199711000-00008.

Abstract

Platelet-activating factor (PAF) is a proinflammatory phospholipid mediator implicated in necrotizing enterocolitis. Regulation of PAF-acetylhydrolase (AH), the enzyme degrading PAF, is poorly understood. In this study we found that administration of a dose of PAF (1.5 microg/kg, i.v.), which does not cause gross intestinal injury, increased plasma and intestinal PAF-AH in the rat. Cycloheximide (CHX, 5 mg/kg, i.v.) reduced the activity of plasma (but not intestinal tissue) AH in control, as well as in PAF-injected rats, and aggravated systemic inflammation and tissue injury in the latter. The intestinal necrosis induced by PAF and CHX was ameliorated by posttreatment with WEB2170 (a PAF antagonist), indicating a role of endogenous PAF in mediating injury. Both WEB2170 and anti-TNF antibody reduced PAF-induced AH activity in intestinal tissue, but not in the plasma. Allopurinol largely prevented the injury induced by PAF and CHX, but had no effect on the up-regulation of AH. We conclude: 1) de novo protein synthesis is required to maintain physiologic AH level in the plasma; 2) PAF up-regulates plasma and intestinal AH activity; 3) CHX enhances the injurious effect of PAF; 4) endogenous PAF and TNF also play a role in the up-regulation of intestinal AH; the former probably mediating the intestinal injury by PAF; and 5) reactive oxygen species may mediate the injurious effect of PAF plus CHX, but do not contribute to the regulation of AH by PAF.

摘要

血小板活化因子(PAF)是一种促炎磷脂介质,与坏死性小肠结肠炎有关。PAF乙酰水解酶(AH)作为降解PAF的酶,其调节机制尚不清楚。在本研究中,我们发现给予大鼠一定剂量的PAF(1.5微克/千克,静脉注射),该剂量不会引起明显的肠道损伤,但会增加大鼠血浆和肠道中的PAF-AH。放线菌酮(CHX,5毫克/千克,静脉注射)可降低对照组以及注射PAF大鼠血浆(而非肠道组织)中AH的活性,并加重后者的全身炎症和组织损伤。PAF和CHX诱导的肠道坏死可通过用WEB2170(一种PAF拮抗剂)进行后处理得到改善,这表明内源性PAF在介导损伤中起作用。WEB2170和抗TNF抗体均可降低PAF诱导的肠道组织中AH的活性,但对血浆中的AH活性无影响。别嘌呤醇在很大程度上预防了PAF和CHX诱导的损伤,但对AH的上调没有影响。我们得出以下结论:1)维持血浆中生理水平的AH需要从头合成蛋白质;2)PAF上调血浆和肠道中AH的活性;3)CHX增强PAF的损伤作用;4)内源性PAF和TNF在肠道AH的上调中也起作用;前者可能通过PAF介导肠道损伤;5)活性氧可能介导PAF加CHX的损伤作用,但不参与PAF对AH的调节。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验